Signet Jewelers, Janux Therapeutics, BW LPG, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Benzinga
U.S. Stock Futures: U.S. stock futures are up, with Dow futures increasing by approximately 0.1% on Tuesday morning.
Signet Jewelers Performance: Signet Jewelers reported better-than-expected earnings and sales for the third quarter, but its shares fell 3.9% in pre-market trading.
Other Stocks Declining: Several stocks, including Janux Therapeutics and Coincheck Group, experienced significant declines in pre-market trading, with Janux down 39.7%.
Market Reactions: Other companies like BW LPG and IREN Ltd also saw their shares drop in pre-market trading following their recent financial announcements.
Analyst Views on JANX
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 55.25 USD with a low forecast of 25.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.640
Low
25.00
Averages
55.25
High
150.00
Current: 14.640
Low
25.00
Averages
55.25
High
150.00
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
